Jumping into growing queue of buyers, Vertex chief targets a slate of new and 'larger' deals ahead
After making it crystal clear that Jeff Leiden plans to keep his hand directly on the wheel of business development following his move from CEO to the executive chairman’s spot, Leiden himself stepped up on Wednesday to personally map out plans for a series of new deals he expects to orchestrate to beef up the pipeline.
During the Q2 call with analysts, Leiden heralded the near-term approval expected for their triple combination for cystic fibrosis. And he made it abundantly clear that a string of new deals regarding gene editing programs for Duchenne muscular dystrophy — buying Exonics and more — are just a prelude to more M&A pacts in the very near future as Reshma Kewalramani preps a move to the CEO suite.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.